Sigumir
Research OnlyA cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cartilage cytamin · Joint peptides · A-4 cartilage peptides
Mostly preclinical · 1 human study
- Preclinical
- 71%
- Human research
- 14%
Based on 7 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Mechanism of Action
Sigumir is a cytamin-class supplement containing peptide complexes derived from cartilage tissue.
Proposed Mechanisms
- Chondrocyte Support - Claimed to support cartilage cell function
- Matrix Integrity - Proposed effects on cartilage extracellular matrix
- Joint Health - Marketed for joint comfort and mobility
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials for joint outcomes
- NOT a treatment for arthritis or joint disorders
- Not approved by any Western regulatory agency
BPC-157
CompatibleBoth target tissue repair - BPC-157 has more preclinical research on connective tissue healing, Sigumir is cytamin supplement for cartilage.
TB-500
CompatibleBoth target tissue repair - TB-500 has broader tissue healing effects, Sigumir specifically targets cartilage.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Sigumir
Related Peptides
Cartalax
AED peptide · Ala-Glu-Asp · cartilage bioregulator
A synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.
GHK
Glycyl-Histidyl-Lysine · GHK tripeptide · Liver cell growth factor
A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
GHK-Cu
Copper Peptide GHK · Glycyl-L-Histidyl-L-Lysine:Copper
GHK-Cu is the copper complex of the GHK tripeptide. Cell and animal studies support matrix-remodeling mechanisms, while small topical human studies give mixed results; these findings do not establish injected GHK-Cu efficacy or safety.